Immuron Limited (ASX:IMC) has generated in excess of $1 million in sales revenue from its flagship product, Travelan, for the financial year ended June 30th 2014.
These revenues are seven times the company’s FY2013 Travelan revenues.
Travelan is clinically-proven to prevent with 90% efficacy the main cause of travellers’ diarrhoea.
According to the World Tourism Organization, diarrheal illness is the most common health impairment associated with international tourism in terms of frequency and economic impact.
The direct-to-wholesale model that Immuron announced last year has substantially increased the company’s gross margins and revenues.
The stable demand for Travelan in the market following a significant price increase is testament both to the quality of the product and to its benefit.
Immuron is capitalised at around $14 million.
Immuron also has two phase 2 clinical programs - one for the treatment of inflamed fatty liver disease, known as Non-Alcoholic Steatohepatitis, and an NIH-sponsored project for the treatment of Alcoholic Steatohepatitis.
Immuron’s main scientific alliances are with Hadassah Medical Center in Israel and Monash University.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.